TIDMHIK
RNS Number : 6022D
Hikma Pharmaceuticals Plc
17 May 2012
Hikma Pharmaceuticals PLC
Results of 2012 Annual General Meeting
LONDON, 17 May 2012 - Hikma Pharmaceuticals PLC ("the Company")
advises that at its Annual General Meeting of shareholders, held at
The Westbury, Bond Street, Mayfair, London W1S 2YF that commenced
at 11:00 am today, 17 May 2012, all resolutions were passed on a
poll. Resolutions 1 to 15, 19 and 20 were passed as ordinary
resolutions and Resolutions 16 to 18 were passed as special
resolutions.
Copies of the resolutions dealing with special business passed
at the Annual General Meeting have been submitted to the UK Listing
Authority for publication through the Listing Authority's Document
Viewing Facility.
The total number of votes cast on the poll for each resolution
is set out below. The number of Ordinary Shares in issue on 17 May
2012 was 196,817,207
Resolution Votes For % Votes Against %
--- ---------------------------- ------------ -------- -------------- -------
To receive the 2011
1 report and accounts 155,153,427 99.93% 113,335 0.07%
--- ---------------------------- ------------ -------- -------------- -------
To declare a final dividend
2 of 7.5 cents per share 155,624,737 100.00% 3,000 0.00%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Deloitte
3 LLP as auditors 153,147,015 98.43% 2,438,663 1.57%
--- ---------------------------- ------------ -------- -------------- -------
Authorise the directors
to set the remuneration
4 of the auditors 153,320,994 98.74% 1,957,215 1.26%
--- ---------------------------- ------------ -------- -------------- -------
Appointment of Robert
5 Pickering 149,388,013 99.26% 1,120,992 0.74%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Samih
6 Darwazah 154,659,516 99.40% 930,962 0.60%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Said
7 Darwazah 155,426,814 99.89% 163,665 0.11%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Mazen
8 Darwazah 153,007,689 98.39% 2,507,390 1.61%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Breffni
9 Byrne 154,991,703 99.74% 397,201 0.26%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Sir
10 David Rowe-Ham 155,404,666 99.88% 185,813 0.12%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Michael
11 Ashton 155,101,725 99.69% 488,754 0.31%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Ali
12 Al-Husry 155,064,379 99.66% 526,100 0.34%
--- ---------------------------- ------------ -------- -------------- -------
Reappointment of Ronald
13 Goode 155,402,166 99.88% 188,313 0.12%
--- ---------------------------- ------------ -------- -------------- -------
To receive and approve
14 the Remuneration Report 143,323,526 96.09% 5,828,053 3.91%
--- ---------------------------- ------------ -------- -------------- -------
Authorise the directors
15 to allot shares 133,975,529 89.20% 16,214,591 10.80%
--- ---------------------------- ------------ -------- -------------- -------
Disapply pre-emption
16 rights 150,497,613 100.00% 4,777 0.00%
--- ---------------------------- ------------ -------- -------------- -------
Authorise the company
17 to buy back shares 150,349,473 99.90% 152,917 0.10%
--- ---------------------------- ------------ -------- -------------- -------
Authorise the company
to call meetings on
18 14 days notice 140,844,552 93.58% 9,662,638 6.42%
--- ---------------------------- ------------ -------- -------------- -------
Rule 9 waiver for buy
19 backs 115,603,336 77.34% 33,870,514 22.66%
--- ---------------------------- ------------ -------- -------------- -------
Rule 9 waiver for LTIP
20 & MIP awards 115,568,727 77.32% 33,905,073 22.68%
--- ---------------------------- ------------ -------- -------------- -------
Waiver of Rule 9 of the City Code on Takeovers and Mergers
In relation to Resolutions 19 and 20, at today's date, the total
number of ordinary shares held by the Concert Party, is 64,790,718
representing a combined shareholding of 32.92 per cent of the
issued share capital of the Company.
Assuming the Share Awards are made in respect of the full number
of shares referred to in the circular to shareholders dated 13
April 2012, that all such grants vest in full, and that all
existing awards LTIP Awards vest in full, and that all Options
currently held by members of the Concert Party were to be fully
exercised and the resulting Ordinary Shares retained by the Concert
Party members, the Concert Party would hold, in aggregate,
interests over 65,341,235 Ordinary Shares, representing 33.11 per
cent of the issued share capital of the Company (as enlarged by the
existing LTIP and MIP Awards and Option Exercises by members of the
Concert Party and the issue of Ordinary Shares to members of the
Concert Party pursuant to the Share Awards, but assuming no other
issue of shares) versus 33.04 per cent of the issued share capital
of the Company on a similar basis, prior to the grant of such Share
Awards.
Were the Company to exercise the buy-back authority to the
exclusion of the Concert Party such that the Concert Party
maintained its current shareholding, that would result in the
Concert Party's percentage interest in the Company's issued share
capital increasing to 36.64 per cent. (assuming that all Existing
LTIP Awards vest in full and all Options held by members of the
Concert Party are exercised and the resulting Ordinary Shares are
retained, but not including the Share Awards granted under
Resolution 20).
If the maximum repurchase of Ordinary Shares authorised was
carried out by the Company and also the maximum number of Share
Awards vested, together with the Existing LTIP Awards and Option
Exercises these changes would increase the aggregate shareholding
of the Concert Party in the Company to 36.71 per cent. (assuming
that that the Concert Party did not sell any Ordinary Shares in the
repurchase of Ordinary Shares and assuming no other issue of
Ordinary Shares).
Declaration of final dividend
The final dividend of 7.5 cents per share will be paid on 24 May
2012 to shareholders on the register on 20 April 2012. Shareholders
who are not resident in Jordan have been given the option of
receiving their dividend in Pounds Sterling. The exchange rate in
respect of this dividend will be $1.6085 to GBP1. The exchange rate
for Jordanian Dinar is fixed to the US Dollar at 1JD to $0.708.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
VP for Investor Relations and Strategy +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non--branded generic
and in--licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2011,
Hikma achieved revenue of $918.0 million and profit attributable to
shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSFLFLWFESEEI
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
